Delivery of Transforming Growth Factor-β3 Plasmid in a Collagen Gel Inhibits Cranial Suture Fusion in Rats

Abstract

Objective

Studies described in this paper were designed to test the hypothesis that an increase in nonviral, plasmid-encoded Tgf-β3 production, localized to the rat posterior frontal suture, prevents programmed suture fusion.

Design

We developed a gene delivery system based on a dense collagen gel to deliver nonviral plasmids that encode for Tgf-β3. Studies were performed to test the ability of this system to rescue rat cranial suture fusion in vitro and in vivo. Immunohistochemical studies were conducted to characterize the possible mechanisms by which increased production and presence of Tgf-β3 protein interferes with suture fusion.

Results

Posterior frontal sutures in the Tgf-β3 plasmid–treated group exhibited 77% to 85% less bony bridging than the collagen control and untreated groups after 15 days in culture. In animals treated with Tgf-β3 plasmid or Tgf-β3 protein, there was a significant reduction in suture fusion in the middle region of the posterior frontal sutures when compared with control groups. In this region the Tgf-β3 plasmid–treated group revealed 70% to 75% less bony bridging than control groups in vivo.

Conclusions

Collagen gel can be formulated to provide release of nonviral plasmid DNA that results in cell transfection and elevated Tgf-β3 protein production. Tgf-β3 is an important regulator of suture fusion, and an increase in plasmid-encoded Tgf-β3 protein is effective in inhibiting programmed suture fusion in rats.

Keywords

collagen gel cranial sutures gene delivery Tgf-β3

Get full access to this article

View all access options for this article.

References

Betz

O.B.

Betz

V.M.

Nazarian

Pilapil

C.G.

Vrahas

M.S.

Bouxsein

M.L.

Gerstenfeld

L.C.

Einhorn

T.A.

Evans

C.H.

Direct percutaneous gene delivery to enhance healing of segmental bone defects. J Bone Joint Surg Am. 2006; 88: 355–365.

Chadduck

W.M.

Chadduck

J.B.

Boop

F.A.

The subarachnoid spaces in craniosynostosis. Neurosurgery. 1992; 30: 867–871.

Chim

Manjila

Cohen

A.R.

Gosain

A.K.

Molecular signaling in pathogenesis of craniosynostosis: the role of fibroblast growth factor and transforming growth factor-beta. Neurosurg Focus. 2011; 31: E7.

Chong

S.L.

Mitchell

Moursi

A.M.

Winnard

P.L.

Losken

H.W.

Bradley

Ozerdem

Azari

Acarfurk

Opperman

L.A.

. Rescue of coronal suture fusion using transforming growth factor-beta 3 (Tgf-beta3) in rabbits with delayed-onset craniosynostosis. Anat Rec A Discov Mol Cell Biol Evol. 2003; 274: 962–971.

Cohen

M.M.

Jr . Suture pathology. In: Cohen

M.M.

MacLean

J.A.

, eds. Craniosynostosis: Diagnosis, Evaluation and Management. New York: Oxford University Press; 2000: 51–68.

Cohen

M.M.

Jr . Craniosynostoses: phenotypic/molecular correlations. Am J Med Genet. 1995; 56: 334–339.

Cohen

M.M.

Jr . Sutural biology and the correlates of craniosynostosis. Am J Med Genet. 1993; 47: 581–616.

Cohen

M.M.

Jr . TGF beta/Smad signaling system and its pathologic correlates. Am J Med Genet. 2003; 116A: 1–10.

De Pollack

Renier

Hott

Marie

P.J.

Increased bone formation and osteoblastic cell phenotype in premature cranial suture ossification (craniosynostosis). J Bone Miner Res. 1996; 11: 401–407.

10.

Dunker

Schmitt

Schuster

Krieglstein

The role of transforming growth factor beta-2, beta-3 in mediating apoptosis in the murine intestinal mucosa. Gastroenterology. 2002; 122: 1364–1375.

11.

Evans

C.H.

Ghivizzani

S.C.

Robbins

P.D.

The 2003 Nicolas Andry Award. Orthopaedic gene therapy. Clin Orthop Relat Res. 2004; 429: 316–329.

12.

Fang

Zhu

Y.Y.

Smiley

Bonadio

Rouleau

J.P.

Goldstein

S.A.

McCauley

L.K.

Davidson

B.L.

Roessler

B.J.

Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl AcadSci U S A. 1996; 93: 5753–5758.

13.

Frazier

B.C.

Mooney

M.P.

Losken

H.W.

Barbano

Moursi

Siegel

M.I.

Richtsmeier

J.T.

Comparison of craniofacial phenotype in craniosynostotic rabbits treated with anti-Tgf-beta2 at suturectomy site. Cleft Palate Craniofac J. 2008; 45: 571–582.

14.

Gault

D.T.

Renier

Marchac

Ackland

F.M.

Jones

B.M.

Intracranial volume in children with craniosynostosis. J Craniofac Surg. 1990; 1: 1–3.

15.

Gault

D.T.

Renier

Marchac

Jones

B.M.

Intracranial pressure and intracranial volume in children with craniosynostosis. Plast Reconstr Surg. 1992; 90: 377–381.

16.

Gosain

A.K.

Machol

4th Gliniak

Halligan

N.L.

TGF-beta1 RNA interference in mouse primary dura cell culture: downstream effects on TGF receptors, FGF-2, and FGF-R1 mRNA levels. Plast Reconstr Surg. 2009; 124: 1466–1473.

17.

Hay

Lemonnier

Fromigue

Marie

P.J.

Bone morphogenetic protein-2 promotes osteoblast apoptosis through a Smad-independent, protein kinase C-dependent signaling pathway. J Biol Chem. 2001; 276: 29028–29036.

18.

Hirosue

Muller

B.G.

Mulligan

R.C.

Langer

Plasmid DNA encapsulation and release from solvent diffusion nanospheres. J Control Release. 2001; 70: 231–242.

19.

Hudgins

R.J.

Cohen

S.R.

Burstein

F.D.

Boydston

W.R.

Multiple suture synostosis and increased intracranial pressure following repair of single suture, nonsyndromal craniosynostosis. Cleft Palate Craniofac J. 1998; 35: 167–172.

20.

Hung

G.L.

Galea-Lauri

Mueller

G.M.

Georgescu

H.I.

Larkin

L.A.

Suchanek

M.K.

Tindal

M.H.

Robbins

P.D.

Evans

C.H.

Suppression of intra-articular responses to interleukin-1 by transfer of the interleukin-1 receptor antagonist gene to synovium. Gene Ther. 1994; 1: 64–69.

21.

Jamsheer

Henggeler

Wierzba

Loeys

De Paepe

Stheneur

Radziag

Matuszewska

Matyas

Latus-Bielenska

A new sporadic case of early-onset Loeys-Dietz syndrome due to the recurrent mutation p.R528C in the TGFBR2 gene substantiates interindividual clinical variability. J Appl Genet. 2009; 50: 405–410.

22.

Jane

J.A.

Persing

J.A.

Neurosurgical treatment of craniosynostosis. In: Cohen

M.M.

MacLean

J.A.

, eds. Craniosynostosis: Diagnosis, Evaluation and Management. New York: Oxford University Press; 2000: 209–227.

23.

Jayappa

Thoendel

Moursi

Premaraj

Transforming growth factor-beta3 induced apoptosis of osteoblasts. J Dent Res. 2008; 87(special issue B): 1593.

24.

Kapp-Simon

K.A.

Figueroa

Jocher

C.A.

Schafer

Longitudinal assessment of mental development in infants with nonsyndromic craniosynostosis with and without cranial release and reconstruction. Plast Reconstr Surg. 1993; 92: 831–839, discussion 840-831.

25.

Kim

K.K.

Chang

Wells

R.G.

Gundberg

C.M.

McCarthy

T.L.

Centrella

Repetitive exposure to TGF-beta suppresses TGF-beta type I receptor expression by differentiated osteoblasts. Gene. 2006; 379: 175–184.

26.

Kwan

M.D.

Wan

D.C.

Wang

Gupta

D.M.

Slater

B.J.

Longaker

M.T.

Microarray analysis of the role of regional dura mater in cranial suture fate. Plast Reconstr Surg. 2008; 122: 389–399.

27.

Lee

S.W.

Choi

K.Y.

Cho

J.Y.

Jung

S.H.

Song

K.B.

Park

E.K.

Choi

J.Y.

Shin

H.I.

Kim

S.Y.

Woo

K.M.

TGF-beta2 stimulates cranial suture closure through activation of the Erk-MAPK pathway. J Cell Biochem. 2006; 98: 981–991.

28.

Lemonnier

Hay

Delannoy

Fromigue

Lomri

Modrowski

Marie

P.J.

Increased osteoblast apoptosis in Apert craniosynostosis: role of protein kinase C and interleukin-1. Am J Pathol. 2001; 158: 1833–1842.

29.

Lin

K.Y.

Nolen

A.A.

Gampper

T.J.

Jane

J.A.

Opperman

L.A.

Ogle

R.C.

Elevated levels of transforming growth factors beta 2 and beta 3 in lambdoid sutures from children with persistent plagiocephaly. Cleft Palate Craniofac J. 1997; 34: 331–337.

30.

Loeys

B.L.

Chen

Neptune

E.R.

Judge

D.P.

Podowski

Holm

Meyers

Leitch

C.C.

Katsanis

Sharifi

A syndrome of altered cardiovascular, craniofacial, neurocognitive and skeletal development caused by mutations in TGFBR1 or TGFBR2. Nat Genet. 2005; 37: 275–281.

31.

Lomri

Lemonnier

Hott

de Parseval

Lajeunie

Munnich

Renier

Marie

P.J.

Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest. 1998; 101: 1310–1317.

32.

Makarov

S.S.

Olsen

J.C.

Johnston

W.N.

Anderle

S.K.

Brown

R.R.

Baldwin

A.S.

Jr Haskill

J.S.

Schwab

J.H.

Suppression of experimental arthritis by gene transfer of interleukin 1 receptor antagonist cDNA. Proc Natl Acad Sci U S A. 1996; 93: 402–406.

33.

Mansukhani

Bellosta

Sahni

Basilico

Signaling by fibroblast growth factors (FGF) and fibroblast growth factor receptor 2 (FGFR2)-activating mutations blocks mineralization and induces apoptosis in osteoblasts. J Cell Biol. 2000; 149: 1297–1308.

34.

McCarthy

J.G.

Glasberg

S.B.

Cutting

C.B.

Epstein

F.J.

Grayson

B.H.

Ruff

Thorne

C.H.

Wisott

Zide

B.M.

Twenty-year experience with early surgery for craniosynostosis: I. Isolated craniofacial synostosis—results and unsolved problems. Plast Reconstr Surg. 1995; 96: 272–283.

35.

McIntyre

Thoendel

Moursi

Premaraj

Effects of transforming growth factor-beta3 on osteoblast proliferation and differentiation. J Dent Res. 2008; 87(special issue B): 878.

36.

Mehrara

B.J.

Spector

J.A.

Greenwald

J.A.

Ueno

Longaker

M.T.

Adenovirus-mediated transmission of a dominant negative transforming growth factor-beta receptor inhibits in vitro mouse cranial suture fusion. Plast Reconstr Surg. 2002; 110: 506–514.

37.

Miller

M.T.

Ocular findings in craniosynostosis. In: Cohen

M.M.

Jr MacLean

, eds. Craniosynostosis: Diagnosis, Evaluation, and Management. New York: Oxford University Press; 2000: 184–196.

38.

Mooney

M.P.

Fellows-Mayle

Losken

H.W.

Dechant

Burrows

A.M.

Smith

T.D.

Cooper

G.M.

Pollock

Siegel

M.I.

Increased intracranial pressure after coronal suturectomy in craniosynostotic rabbits. J Craniofac Surg. 1999; 10: 104–110.

39.

Mooney

M.P.

Losken

H.W.

Moursi

A.M.

Bradley

Azari

Acarturk

T.O.

Cooper

G.M.

Thompson

Opperman

L.A.

Siegel

M.I.

Anti-TGF-beta2 antibody therapy inhibits postoperative resynostosis in craniosynostotic rabbits. Plast Reconstr Surg. 2007a; 119: 1200–1212, discussion 1213-1205.

40.

Mooney

M.P.

Losken

H.W.

Moursi

A.M.

Shand

J.M.

Cooper

G.M.

Curry

Burrows

A.M.

Steinicki

E.J.

Losee

J.E.

. Postoperative anti-Tgf-beta2 antibody therapy improves intracranial volume and craniofacial growth in craniosynostotic rabbits. J Craniofac Surg. 2007b; 18: 336–346, discussion 347-339.

41.

Mooney

M.P.

Moursi

A.M.

Opperman

L.A.

Siegel

M.I.

Cytokine therapy for craniosynostosis. Expert Opin Biol Ther. 2004; 4: 279–299.

42.

Moreira-Gonzalez

Jackson

I.T.

Miyawaki

Barakat

DiNick

Clinical outcome in cranioplasty: critical review in long-term follow-up. J Craniofac Surg. 2003; 14: 144–153.

43.

Moursi

A.M.

Winnard

P.L.

Fryer

Mooney

M.P.

Delivery of transforming growth factor-beta2-perturbing antibody in a collagen vehicle inhibits cranial suture fusion in calvarial organ culture. Cleft Palate Craniofac J. 2003; 40: 225–232.

44.

Moursi

A.M.

Winnard

P.L.

Winnard

A.V.

Rubenstrunk

J.M.

Mooney

M.P.

Fibroblast growth factor 2 induces increased calvarial osteoblast proliferation and cranial suture fusion. Cleft Palate Craniofac J. 2002; 39: 487–496.

45.

Ochiya

Nagahara

Sano

Itoh

Terada

Biomaterials for gene delivery: atelocollagen-mediated controlled release of molecular medicines. Curr Gene Ther. 2001; 1: 31–52.

46.

Opperman

L.A.

Adab

Gakunga

P.T.

Transforming growth factor-beta 2 and TGF-beta 3 regulate fetal rat cranial suture morphogenesis by regulating rates of cell proliferation and apoptosis. Dev Dyn. 2000; 219: 237–247.

47.

Opperman

L.A.

Chhabra

Cho

R.W.

Ogle

R.C.

Cranial suture obliteration is induced by removal of transforming growth factor (TGF)-beta 3 activity and prevented by removal of TGF-beta 2 activity from fetal rat calvaria in vitro. J Craniofac Genet Dev Biol. 1999; 19: 164–173.

48.

Opperman

L.A.

Fernandez

C.R.

Rawlins

J.T.

Erk1/2 signaling is required for Tgf-beta2-induced suture closure. Dev Dyn. 2006; 235: 1292–1299.

49.

Opperman

L.A.

Galanis

Williams

A.R.

Adab

Transforming growth factor-beta3 (Tgf-beta3) down-regulates Tgf-beta3 receptor type I (Tbetar-I) during rescue of cranial sutures from osseous obliteration. Orthod Craniofac Res. 2002a; 5: 5–16.

50.

Opperman

L.A.

Moursi

A.M.

Sayne

J.R.

Wintergerst

A.M.

Transforming growth factor-beta 3(Tgf-beta3) in a collagen gel delays fusion of the rat posterior interfrontal suture in vivo. Anat Rec. 2002b; 267: 120–130.

51.

Opperman

L.A.

Nolen

A.A.

Ogle

R.C.

TGF-beta 1, TGF-beta 2, and TGF-beta 3 exhibit distinct patterns of expression during cranial suture formation and obliteration in vivo and in vitro. J Bone Miner Res. 1997; 12: 301–310.

52.

Panchal

Uttchin

Management of craniosynostosis. Plast Reconstr Surg. 2003; 111: 2032–2048, quiz 2049.

53.

Perez

Sanchez

Putnam

Ting

Langer

Alonso

M.J.

Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J Control Release. 2001; 75: 211–224.

54.

Persing

J.A.

Jane

J.A.

Edgerton

M.A.

Surgical treatment of craniosynostosis. In: Persing

J.A.

Jane

J.A.

Edgerton

M.A.

, eds. Scientific Foundations and Surgical Treatment of Craniosynostosis. Baltimore: Williams and Wilkins; 1989: 87–95.

55.

Poisson

Sciote

J.J.

Koepsel

Cooper

G.M.

Opperman

L.A.

Mooney

M.P.

Transforming growth factor-beta isoform expression in the perisutural tissues of craniosynostotic rabbits. Cleft Palate Craniofac J. 2004; 41: 392–402.

56.

Pollack

I.F.

Losken

H.W.

Biglan

A.W.

Incidence of increased intracranial pressure after early surgical treatment of syndromic craniosynostosis. Ped Neurosurg. 1996; 24: 202–209.

57.

Posnick

J.C.

Ruiz

R.L.

The craniofacial dysostosis syndromes: current surgical thinking and future directions. Cleft Palate Craniofac J. 2000; 37: 433–441.

58.

Premaraj

Mundy

B.L.

Morgan

Winnard

P.L.

Mooney

M.P.

Moursi

A.M.

Sustained delivery of bioactive cytokine using a dense collagen gel vehicle collagen gel delivery of bioactive cytokine. Arch Oral Biol. 2006; 51: 325–333.

59.

Premaraj

Mundy

Parker-Barnes

Winnard

P.L.

Moursi

A.M.

Collagen gel delivery of Tgf-beta3 non-viral plasmid DNA in rat osteoblast and calvarial culture. Orthod Craniofac Res. 2005; 8: 320–322.

60.

Roth

D.A.

Gold

L.I.

Han

V.K.

McCarthy

J.G.

Sung

J.J.

Wisoff

J.H.

Longaker

M.T.

Immunolocalization of transforming growth factor beta 1, beta 2, and beta 3 and insulin-like growth factor I in premature cranial suture fusion. Plast Reconstr Surg. 1997a; 99: 300–309, discussion 310-306.

61.

Roth

D.A.

Longaker

M.T.

McCarthy

J.G.

Rosen

D.M.

McMullen

H.F.

Levine

J.P.

Sung

Gold

L.I.

Studies in cranial suture biology: part I. Increased immunoreactivity for TGF-beta isoforms (beta 1, beta 2, and beta 3) during rat cranial suture fusion. J Bone Miner Res. 1997b; 12: 311–321.

62.

Sano

Maeda

Nagahara

Ochiya

Honma

Itoh

Miyata

Fujioka

Atelocollagen for protein and gene delivery. Adv Drug Deliv Rev. 2003; 55: 1651–1677.

63.

Scherer

Schillinger

Putz

Stemberger

Plank

Nonviral vector loaded collagen sponges for sustained gene delivery in vitro and in vivo. J Gene Med. 2002; 4: 634–643.

64.

Shuper

Merlob

Grunebaum

Reisner

S.H.

The incidence of isolated craniosynostosis in the newborn infant. Am J Dis Child 1985; 139: 85–86.

65.

Singer

Bower

Southall

Goldblatt

Craniosynostosis in Western Australia, 1980-1994: a population-based study. Am J Med Genet. 1999; 83: 382–387.

66.

Slater

B.J.

Kwan

M.D.

Gupta

D.M.

Amasha

R.R.

Wan

D.C.

Longaker

M.T.

Dissecting the influence of regional dura mater on cranial suture biology. Plast Reconstr Surg. 2008a; 122: 77–84.

67.

Slater

B.J.

Kwan

M.D.

Gupta

D.M.

Lee

J.K.

Longaker

M.T.

The role of regional posterior frontal dura mater in the overlying suture morphology. Plast Reconstr Surg. 2009; 123: 463–469.

68.

Slater

B.J.

Lenton

K.A.

Kwan

M.D.

Gupta

D.M.

Wan

D.C.

Longaker

M.T.

Cranial sutures: a brief review. Plast Reconstr Surg. 2008b; 121: 170e–178e.

69.

Song

H.M.

Fong

K.D.

Nacamuli

R.P.

Warren

S.M.

Fang

T.D.

Mathy

J.A.

Cowan

C.M.

Aakimi

O.O.

Longakey

M.T.

Mechanisms of murine cranial suture patency mediated by a dominant negative transforming growth factor-beta receptor adenovirus. Plast Reconstr Surg. 2004; 113: 1685–1697.

70.

Tug

Loeys

De Paepe

Aydin

Gideroglu

K.A.

Turkish patient of typical Loeys-Dietz syndrome with a TGFBR2 mutation. Genet Couns. 2010; 21: 225–232.

71.

Wang

E.A.

Israel

D.I.

Kelly

Luxenberg

D.P.

Bone morphogenetic protein-2 causes commitment and differentiation in C3H10T1/2 and 3T3 cells. Growth Factors. 1993; 9: 57–71.

72.

Warren

S.M.

Brunet

L.J.

Harland

R.M.

Economides

A.N.

Longaker

M.T.

The BMP antagonist noggin regulates cranial suture fusion. Nature. 2003; 422: 625–629.

73.

Williams

Cohen

Burstein

Hudgins

Boydston

Simms

A longitudinal, statistical study of reoperation rates in craniosynostosis. Plast Reconstr Surg. 1997; 100: 305–310.

74.

Malladi

Chiou

Longaker

M.T.

Isolation and characterization of posterofrontal/sagittal suture mesenchymal cells in vitro. Plast Reconstr Surg. 2007; 119: 819–829.

75.

Zhou

Y.X.

Chen

Brodie

S.G.

Deng

C.X.A.

Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures. Hum Mol Genet. 2000; 9: 2001–2008.

76.

Zimmermann

K.C.

Bonzon

Green

D.R.

The machinery of programmed cell death. Pharmacol Ther. 2001; 92: 57–70.